413599-62-9
413599-62-9 結構式
基本信息
ZD-4190
ZD 4190
ZD4190
4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[2-(1H-1,2,3-triazol-1-yl)ethoxy]-
物理化學性質
| 報價日期 | 產品編號 | 產品名稱 | CAS號 | 包裝 | 價格 |
| 2025/05/22 | HY-U00002 | ZD-4190 | 413599-62-9 | 1 mg | 516元 |
| 2025/05/22 | HY-U00002 | 413599-62-9 ZD-4190 | 413599-62-9 | 5mg | 1363元 |
| 2025/05/22 | HY-U00002 | 413599-62-9 ZD-4190 | 413599-62-9 | 10 mM * 1 mLin DMSO | 1377元 |
常見問題列表
| Target | Value |
|
KDR
() | |
|
Flt-1
() |
ZD4190 exhibits cytotoxic activity against the tumor cells.
ZD4190 (100 mg/kg, p.o.) effectively delays MDA-MB-435 tumor growth in mice. In ZD4190-treated tumors, 18F-FPPRGD2 uptake has decreased significantly relative to baseline by 26.74±8.12% (p<0.05) on day 1 and by 41.19±6.63% (p<0.01) on day 3, then has returned to baseline on day 7. Tumor uptake of 18F-FLT has also decreased on both day 1 and day 3 after initiation of ZD4190 treatment. However, ZD4190 does not significantly change 18F-FDG uptake in tumors, compared with the control group. ZD4190 (50?mg/kg, p.o.) prevents outgrowth of residual tumour in a muscle model of minimal residual carcinoma. ZD4190 (12.5-100 mg/kg, p.o.) produces a dose-dependent reduction in K(trans) in PC-3 prostate tumors. At 100 mg/kg, ZD4190 reduces K(trans) in PC-3 tumors by 31% following 2 doses and by 53% following 8 doses.